Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5206962
Max Phase: Preclinical
Molecular Formula: C19H18N4O2
Molecular Weight: 334.38
Associated Items:
ID: ALA5206962
Max Phase: Preclinical
Molecular Formula: C19H18N4O2
Molecular Weight: 334.38
Associated Items:
Canonical SMILES: Cc1ccccc1NC(=O)Nc1cccc(Oc2ccc(N)nc2)c1
Standard InChI: InChI=1S/C19H18N4O2/c1-13-5-2-3-8-17(13)23-19(24)22-14-6-4-7-15(11-14)25-16-9-10-18(20)21-12-16/h2-12H,1H3,(H2,20,21)(H2,22,23,24)
Standard InChI Key: SJUHELYQYYGPKA-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 334.38 | Molecular Weight (Monoisotopic): 334.1430 | AlogP: 4.41 | #Rotatable Bonds: 4 |
Polar Surface Area: 89.27 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.40 | CX Basic pKa: 5.96 | CX LogP: 3.68 | CX LogD: 3.67 |
Aromatic Rings: 3 | Heavy Atoms: 25 | QED Weighted: 0.66 | Np Likeness Score: -1.45 |
1. Yan YY, Zhang XX, Xiao Y, Shen XB, Jian YJ, Wang YM, She ZH, Liu MM, Liu XH.. (2022) Design and Synthesis of a 2-Amino-pyridine Derivative as a Potent CDK8 Inhibitor for Anti-colorectal Cancer Therapy., 65 (19.0): [PMID:36126227] [10.1021/acs.jmedchem.2c01042] |
Source(1):